Faculty Collaboration Database

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv 2025 Oct 28;9(20):5382-5396

Date

07/24/2025

Pubmed ID

40706035

Pubmed Central ID

PMC12597645

DOI

10.1182/bloodadvances.2024015014

Scopus ID

2-s2.0-105022684848 (requires institutional sign-in at Scopus site)   19 Citations

Abstract

Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell-associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.

Author List

Ahmed N, Thiruvengadam SK, Hamadani M, Hu ZH, Grover N, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang M, Kim S, Bye M, Kharfan-Dabaja MA, Sauter C, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan B, Nunes A, Dalton D, Kloos I, Lee D, Xu H, Pasquini MC, Herrera AF

Authors

Mehdi Hamadani MBBS Professor in the Medicine department at Medical College of Wisconsin
Peiman Hematti MD Professor in the Medicine department at Medical College of Wisconsin
Soyoung Kim PhD Associate Professor in the Data Science Institute department at Medical College of Wisconsin
Amy Moskop MD Associate Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Female
Humans
Immunotherapy, Adoptive
Lymphoma, Mantle-Cell
Male
Middle Aged
Prospective Studies
Recurrence
Treatment Outcome